Allotransplantation

Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022

Retrieved on: 
Friday, May 20, 2022
Cancer, Mythic Imagination Institute, Investigational New Drug, NSG, Company, Doctor of Pharmacy, Acute leukemia, Disease, Infection, CCR7, American, HSCT, Doctor of Philosophy, AML, Patient, ILC, CXCR4, Lymphatic system, Graft-versus-host disease, Adult, Mortality, SCID, Cell, Research, Gene, FDA, Mouse, Imagine, Allotransplantation, IND, Trial, NK, Virus, Program, Leukemia, CCR9, CD161, Prognosis, Immunodeficiency, ALL, Immune system, GLOBE, Vaccine, Dietary supplement, MD

This research provides further evidence that our lymphoid progenitors have a plasticity that allows them to differentiate into both T cells and NK cells.

Key Points: 
  • This research provides further evidence that our lymphoid progenitors have a plasticity that allows them to differentiate into both T cells and NK cells.
  • Innate lymphoid cells (ILCs) are innate counterparts of T cells that contribute to immune responses by secreting effector cytokines and regulating the functions of other innate and adaptive immune cells.
  • Through its patented ex vivo lymphoid niche technology, Smart Immune develops a thymus empowered T cell therapy platform called ProTcell.
  • The Smart Immune ProTcell platform generates allogenic T-cell progenitors that provide fully functional polyclonal T-cells within 3 months through thymic education.

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

Retrieved on: 
Wednesday, May 18, 2022
Chemistry, Good manufacturing practice, Good tissue practice, Engineering, Company, Annual general meeting, U.S. Securities and Exchange Commission, Annual report, Patient, Vii, Sterilization, COVID-19, Research, Forward-looking statement, Board, CGMP, Hospital, Board of directors, THE, ALL, SEC, Growth, CARD, Allotransplantation, Security (finance), Form 3, Risk, Tissue, Pharmaceutical industry

MARIETTA, Ga., May 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its 2022 Annual Meeting of Shareholders, which is scheduled to be held on June 7, 2022. The presentation, and other important shareholder materials, are available at www.VoteMIMEDX.com. 

Key Points: 
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine Models for Novel Gene Therapy in Maple Syrup Urine Disease at the 25th ASGCT Meeting

Retrieved on: 
Saturday, May 21, 2022
Research, Genetics, Clinical Trials, Biotechnology, General Health, University, Pharmaceutical, Health, Science, Education, BCKDHA, School, University of Massachusetts Medical School, Leucine, Allotransplantation, MSUD, University, Diet, Haemophilia, Animal, ASC, Phenotype, Gene, Clinic, Biomedical sciences, Therapy, Clinical trial, DBT, UMass Memorial Health, Research, Mouse, Cerebral edema, UMMS, RNA, Duke University School of Medicine, Genetic disorder, University of Massachusetts, Maple, Commonwealth, Doctor of Philosophy, Health, BCAA, Clinic for Special Children, Partnership, Human, Maple syrup urine disease, Graduate school, Cell, MD, CSC, Valine, Organic acid, Lists of diseases, Patient, Society, BCKDHB, Industry, AAV, Calf, Life, Isoleucine, Safety, Intussusception (medical disorder), Mayo Clinic Graduate School of Biomedical Sciences, Mutation, Precision medicine, CEO, Vaccine, Milk, Medical device, Pharmaceutical industry, Research, Genetics, Clinical Trials, Biotechnology, General Health, University, Pharmaceutical, Health, Science, Education

The partnership designed a dual-function AAV9 gene replacement vector that was administered via intravenous (IV) injection.

Key Points: 
  • The partnership designed a dual-function AAV9 gene replacement vector that was administered via intravenous (IV) injection.
  • Surviving mice grew and behaved similar to normal littermates and had normal or nearly normal biochemical markers with unrestricted diet for 16 weeks.
  • As compared to MSUD patients, MSUD calves exhibit a similar phenotype and are closely matched for size and metabolic rate.
  • In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education.

ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.

Retrieved on: 
Tuesday, May 17, 2022
Research, FDA, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, PM, TCID50, International Society, VIII, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, VP, Annual general meeting, Lists of diseases, Haemophilia, Doctor of Philosophy, European Medicines Agency, Patient, Poster, Unfolded protein response, Gene editing, Therapy, Thrombosis, Clinical trial, Immunotherapy, Society, ISTH, AM, Haemophilia A, Gene, DOI, FDA, IND, Allotransplantation, COMP, Toxicology, EMA, Program, Congress, Safety, Biology, Maple syrup urine disease, Cell, Committee, International Society on Thrombosis and Haemostasis, ASC, CEO, Pharmaceutical industry, Vaccine, Hemostasis, Mouse

These studies were included in a filing to the U.S. Food and Drug Administration (FDA) leading to IND clearance of ASC618 .

Key Points: 
  • These studies were included in a filing to the U.S. Food and Drug Administration (FDA) leading to IND clearance of ASC618 .
  • We are thrilled to bring a second-generation gene therapy treatment to patients with Hemophilia A.
  • Thousands of cell and gene therapy developers, including basic and clinical investigators represent the academic, regulatory, and biotechnology sectors.
  • Hemophilia A gene therapy: current and next-generation approaches, Expert Opinion on Biological Therapy 2022 Jan 6;1-17, DOI: 10.1080/14712598.2022.2002842
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005908/en/

MIMEDX to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 5, 2022
Sterilization, GLOBE, Engineering, Patient, Allotransplantation, Good tissue practice, Group, Bank of America, Tissue, Bank, Investor, Security (finance)

MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced that senior management will participate in the following investor conferences:

Key Points: 
  • MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced that senior management will participate in the following investor conferences:
    Institutional investors interested in meeting with senior management may contact their respective Bank of America or H.C. Wainwright representative.
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

Retrieved on: 
Wednesday, May 4, 2022
U.S. Securities and Exchange Commission, ADAP, Private Securities Litigation Reform Act, University, Senior, CSO, Nasdaq, GLOBE, SVP, Engineering, IPSC, Doctor of Philosophy, Immunotherapy, Security (finance), Cancer, Annual report, ADP, SPEAR, Sumathi Best Television Current Reporting Award, TCR, Natural science, Allotransplantation, GSK, PSLRA, Pharmaceutical industry, Immunocore, Immunocore

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.

Key Points: 
  • PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.
  • Jo Brewer is an exceptional scientific leader, and I am delighted that she has accepted the newly created CSO role, leading our ongoing scientific research, and developing future autologous and allogeneic therapies, said Adrian Rawcliffe, Adaptimmunes Chief Executive Officer.
  • She has played a crucial role in our collaborations with Astellas and Genentech.
  • Brewer served as Senior Vice President, Allogeneic Research at Adaptimmune since December 2019.

Global Mesenchymal Stem Cells Market Research Report to 2027 - Featuring Astellas Pharma, Axol Biosciences and BrainStorm Cell Therapeutics Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 29, 2022
Biotechnology, Health, Genetics, Science, Research, R, Business Growth Fund, USD, Value, Investment, Stem cell, COVID-19, Decision-making, Technology, Growth, Compound annual growth rate, Acquisition, Use, CAGR, Customer support, Market share analysis, Allotransplantation, Strategic management, Certification, Retail, Fine chemical

What are the inhibiting factors and impact of COVID-19 shaping the Global Mesenchymal Stem Cells Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Mesenchymal Stem Cells Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Mesenchymal Stem Cells Market?
  • What is the market share of the leading vendors in the Global Mesenchymal Stem Cells Market?
  • What modes and strategic moves are considered suitable for entering the Global Mesenchymal Stem Cells Market?

MIMEDX Comments on Prescience Point’s Recent Filing

Retrieved on: 
Friday, April 29, 2022
Good manufacturing practice, CGMP, U.S. Securities and Exchange Commission, Time, Director, Patient, Annual report, Risk, GLOBE, Annual general meeting, Sterilization, Tissue, COVID-19, Shareholder, Forward-looking statement, Growth, Chemistry, Health, Good tissue practice, Vii, Company, Hospital, Security (finance), Ethics, Culture, Regenerative medicine, Research, Engineering, NASDAQ, Committee, Board, FOR, Allotransplantation, Anas El Asbahi, ALL, SEC, CARD, Form 3, THE, Management

MARIETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today issued the following statement in response to the filing of a Schedule 13D with the Securities and Exchange Commission by Prescience Point Capital Management (“Prescience Point”):

Key Points: 
  • We believe that a companys integrity and credibility stem from exemplary leadership, and MIMEDX is not willing to compromise on our core values and commitments.
  • Prescience Points repeated, distracting and costly attempts to replace and remove members of our Board, including directors previously nominated by Prescience Point, are simply not in the best interests of all MIMEDX shareholders, and serve to potentially impede the progress we are making.
  • The MIMEDX Annual Meeting of Shareholders will be held on June 7, 2022.
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.

ALLOSOURCE SPONSORED DEVAUGHN LEVY-HAGAN MEMORIAL BASKETBALL GAME RAISES MONEY FOR MENTAL HEALTH/SUICIDE PREVENTION

Retrieved on: 
Wednesday, April 27, 2022
NFL, CEO, Athlete, Awareness, Devaughn, University of Colorado, Cherry Creek High School, Association, CU, National, Allotransplantation, Metropolitan Opera, Organization, American Association of Tissue Banks, Mental, Patient, Cell, Surgeon, Mental health, Skin, Public sector banks in India, Hope, American Association, Hockey, University, Medicine

CENTENNIAL, Colo., April 27, 2022 /PRNewswire/ --AlloSource, Colorado's largest homegrown bioscience company whose business focuses on creating innovative cellular and tissue allografts to help surgeons heal their patients, sponsored the DeVaughn Levy-Hagan Memorial Basketball Game for Mental Health/Suicide Prevention yesterday evening at Cherry Creek High School.

Key Points: 
  • CENTENNIAL, Colo., April 27, 2022 /PRNewswire/ --AlloSource, Colorado's largest homegrown bioscience company whose business focuses on creating innovative cellular and tissue allografts to help surgeons heal their patients, sponsored the DeVaughn Levy-Hagan Memorial Basketball Game for Mental Health/Suicide Prevention yesterday evening at Cherry Creek High School.
  • Proceeds from the event helped support StoryHealers workshops, an organization where participants overcoming mental health challenges write and perform their stories of hope and healing.
  • "It's great to come together and support a local community organization while raising awareness for community mental health," said Tom Cycyota, AlloSource President and CEO.
  • "The products we create help people heal physically, but we believe it is just as important to embrace mental health, as physical and mental wellbeing are often connected."

Bone Grafts and Substitutes Market to Expand at CAGR of 4.9% during the forecast period, TMR Report

Retrieved on: 
Thursday, April 21, 2022
Awareness, International Osteoporosis Foundation, Chronic kidney disease-mineral and bone disorder, Woman, Fracture, Allotransplantation, Incidence, Consistency, TMR, Infection, Growth, Surgeon, China Biologic Products, Man, Animal, Investment, Prevalence, Risk, Dentistry, Thermoplastic

Rising incidence of bone and joint disorders leading to continuous strides in orthopaedic surgeries is fueling the growth of the bone grafts and substitutes market.

Key Points: 
  • Rising incidence of bone and joint disorders leading to continuous strides in orthopaedic surgeries is fueling the growth of the bone grafts and substitutes market.
  • Increasing prevalence of chronic bone diseases, spurt in demand for treatment of complex bone disorders, and substantial increase in patient awareness and healthcare expenditures cements growth of the bone grafts and substitutes market.
  • Consistent R&D for improved bone grafts has led to the advent of novel biological products such as autologous, allogenic, and synthetic bone grafts.
  • Presence of modern healthcare infrastructure, evolution of bone graft and substitute products, and substantial expenditure on advanced surgical procedures fuels the growth of the bone grafts and substitutes market of the region
    Substantial R&D leading to the advent of a range of biological products such as allogenic, autologous, and synthetic bone grafts stimulates the demand in bone grafts and substitutes market
    Some of the key players operating in the bone grafts and substitutes market are;